Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study

Pathak, S; Vince, B; Kelsh, D; Setnik, B; Nangia, N; DiPetrillo, L; Puhl, MD; Sun, L; Stanford, AD; Ehrich, E

Pathak, S (reprint author), Alkermes Inc, 852 Winter St, Waltham, MA 02451 USA.

JOURNAL OF CLINICAL PHARMACOLOGY, 2019; 59 (2): 218

Abstract

Samidorphan is a mu-opioid receptor antagonist in development for the treatment of schizophrenia, in combination with olanzapine, and major depressive......

Full Text Link